AU2011239683A1 - Compositions and methods for treating visual disorders - Google Patents

Compositions and methods for treating visual disorders Download PDF

Info

Publication number
AU2011239683A1
AU2011239683A1 AU2011239683A AU2011239683A AU2011239683A1 AU 2011239683 A1 AU2011239683 A1 AU 2011239683A1 AU 2011239683 A AU2011239683 A AU 2011239683A AU 2011239683 A AU2011239683 A AU 2011239683A AU 2011239683 A1 AU2011239683 A1 AU 2011239683A1
Authority
AU
Australia
Prior art keywords
alkyl
substituted
retinal
oil
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011239683A
Other languages
English (en)
Inventor
Alan C. Foster
Yong-xin LI
Ursula V. Staubli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2011239683A1 publication Critical patent/AU2011239683A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2011239683A 2010-04-15 2011-04-13 Compositions and methods for treating visual disorders Abandoned AU2011239683A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32463210P 2010-04-15 2010-04-15
US61/324,632 2010-04-15
PCT/US2011/032325 WO2011130411A1 (en) 2010-04-15 2011-04-13 Compositions and methods for treating visual disorders

Publications (1)

Publication Number Publication Date
AU2011239683A1 true AU2011239683A1 (en) 2012-11-08

Family

ID=44009992

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011239683A Abandoned AU2011239683A1 (en) 2010-04-15 2011-04-13 Compositions and methods for treating visual disorders

Country Status (8)

Country Link
US (1) US20110257186A1 (cg-RX-API-DMAC7.html)
EP (1) EP2558100A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013523892A (cg-RX-API-DMAC7.html)
KR (1) KR20130092976A (cg-RX-API-DMAC7.html)
AU (1) AU2011239683A1 (cg-RX-API-DMAC7.html)
CA (1) CA2796345A1 (cg-RX-API-DMAC7.html)
RU (1) RU2012148214A (cg-RX-API-DMAC7.html)
WO (1) WO2011130411A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600127037A1 (it) * 2016-12-15 2018-06-15 Oftalab S R L Soluzione oftalmica di verde di lissamina e suo uso in oftalmologia
CN109908327A (zh) * 2019-03-12 2019-06-21 广州陈锦济生物科技有限公司 一种用于治疗近视的眼药水及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
PL378366A1 (pl) * 2003-01-13 2006-04-03 Cortex Pharmaceuticals, Inc. Sposób leczenia osłabienia funkcji poznawczych spowodowanego deprywacją snu i stresem
EP2010174A4 (en) * 2006-04-20 2012-05-09 Univ California PHARMACOLOGICAL MODULATION OF POSITIVE AMPA-RECEPTOR MODULATOR EFFECT ON NEUROTROPHINEXPRESSION
US20080139472A1 (en) * 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
ZA200904826B (en) * 2007-01-03 2010-09-29 Cortex Pharma Inc 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
CA2674321A1 (en) 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
NZ584098A (en) * 2007-09-20 2012-05-25 Cortex Pharma Inc 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
JP2013523892A (ja) 2013-06-17
RU2012148214A (ru) 2014-05-20
EP2558100A1 (en) 2013-02-20
WO2011130411A1 (en) 2011-10-20
KR20130092976A (ko) 2013-08-21
CA2796345A1 (en) 2011-10-20
US20110257186A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
JP7519413B2 (ja) 眼科用薬剤組成物、眼科用キット、及びその医学的応用
JP2010536797A5 (cg-RX-API-DMAC7.html)
JP2009511632A5 (cg-RX-API-DMAC7.html)
RS63136B9 (sr) Lekoviti sastav koji sadrži tivozanib
US20090118262A1 (en) Non-Aqueous Water-Miscible Materials as Vehicles for Drug Delivery
MXPA06000408A (es) Suministro de un farmaco por medio de suministro periocular o subconjuntival de un profarmaco en una microparticula polimerica.
JP2021518352A (ja) チモロールを含む医薬組成物
JP2017503028A (ja) 眼内血管新生及び/または漏出を治療するための組成物及び方法
US20170172959A1 (en) D-serine for the treatment of visual system disorders
US20110257186A1 (en) Compositions and methods for treating visual disorders
JP2019534269A5 (cg-RX-API-DMAC7.html)
AU2004296748B2 (en) Prevention and/or reduction of photoreceptor degeneration with retinoids
JP2013501794A (ja) 目の疾患を治療するためのイソチオゾール
CN117355292A (zh) 用于预防或治疗眼病的抑制n-氧代吡啶化合物出现的眼科组合物
JP2002356431A (ja) ステロイドを有効成分とする網脈絡膜疾患治療剤
CN111358751B (zh) 眼用药物组合物、眼用药盒及其医药用途
US20130197002A1 (en) Brimonidine for treating visual disorders mediated by central visual projections from the eye
CA3036474C (en) Therapeutic agent for an ophthalmic disease comprising a vegf receptor inhibitor
US20130267488A1 (en) Pharmaceutical formulation having neuroprotective activity
HK40074896A (en) Ophthalmic pharmaceutical composition, ophthalmic kit, and medical application thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted